文献速递神经肿瘤

WHO III级脑膜瘤中雌激素受体的预后价值:单中心长期随访研究

Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution.
PubMed 文献 · J Neurosurg · 2017-08-18

该单中心回顾性队列纳入2003至2008年病理诊断为WHO III级脑膜瘤的87例患者并随访至少7年,分析临床特征、治疗与预后。ER阳性患者无进展生存期(PFS)和总生存期(OS)均显著差于ER阴性患者,多因素分析显示ER表达是PFS和OS的独立预后因素。

要点

  • 87例WHO III级脑膜瘤患者随访至少7年,ER阳性者PFS(p=0.003)和OS(p<0.001)均显著更差。
  • 多因素分析显示ER表达是PFS(p=0.008)和OS(p<0.001)的独立预后因素。
  • 全切较次全切PFS(p=0.001)和OS(p=0.027)更长,辅助放疗与OS相关(p=0.034)。

核心结论

  • ER阳性表达的WHO III级脑膜瘤患者预后远差于ER弱阳性或ER阴性患者。
  • ER是WHO III级脑膜瘤患者PFS和OS的独立预后因素。
  • 作者发现更彻底的肿瘤切除以及术后放疗可能延长患者生存时间。

研究设计与样本

  • 单中心回顾性队列研究,纳入2003至2008年病理诊断为WHO III级脑膜瘤的87例患者,随访至少7年。

主要发现

  • 纳入横纹肌样型12例、乳头型12例、间变性63例。
  • 平均无进展生存期(PFS)为56.2±49.8个月,平均总生存期(OS)为68.7±47.4个月。
  • 3种组织学亚型间PFS(p=0.929)和OS(p=0.688)均无显著差异。
  • 全切患者较次全切患者PFS更长(p=0.001)、OS更长(p=0.027)。
  • 辅助放疗与OS相关(p=0.034),但与PFS无关(p=0.433)。

关键数值与推荐

  • 复发患者较原发患者PFS更差(p<0.001)。
  • 恶性转化患者较无恶性转化患者PFS(p=0.002)和OS(p=0.019)均更差。
  • ER阳性患者较ER阴性患者PFS(p=0.003)和OS(p<0.001)均显著更差。
  • 孕激素受体与患者结局未见关联。
  • 多因素分析显示ER表达是PFS(p=0.008)和OS(p<0.001)的独立预后因素。

临床怎么用

  • 作者认为更彻底的肿瘤切除以及术后放疗可能延长WHO III级脑膜瘤患者的生存时间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE Malignant meningioma is rare and classified as Grade III in the WHO classification of CNS tumors. However, the presence of estrogen receptor (ER) in WHO Grade III meningiomas and its correlation with patients' outcomes are still unclear. In this single-center cohort study, the authors analyzed clinical features, treatment, and prognosis of these malignant tumors in patients with long-term follow-up. METHODS A total of 87 patients who were pathologically diagnosed with WHO Grade III meningiomas between 2003 and 2008 were enrolled in this study and followed for at least 7 years. Clinical information was collected to analyze the factors determining the prognosis. RESULTS Twelve patients with rhabdoid, 12 with papillary, and 63 with anaplastic meningioma were included. The mean progression-free survival (PFS) and overall survival (OS) were 56.2 ± 49.8 months and 68.7 ± 47.4 months, respectively. No significant differences were observed among the 3 histological subtypes in either PFS (p = 0.929) or OS (p = 0.688). Patients who received gross-total resection had a longer PFS (p = 0.001) and OS (p = 0.027) than those who received subtotal resection. Adjuvant radiotherapy was associated with OS (p = 0.034) but not PFS (p = 0.433). Compared with primary meningiomas, patients with recurrent disease had worse PFS (p < 0.001). For patients who had malignant transformations, the prognosis was poorer than for patients without malignant transformations for both PFS (p = 0.002) and OS (p = 0.019). ER-positive patients had a significantly worse prognosis than ER-negative patients regarding both PFS (p = 0.003) and OS (p < 0.001), whereas no association between progesterone receptor and patients' outcomes was observed. Multivariate analysis demonstrated that ER expression was an independent prognostic factor for both PFS (p = 0.008) and OS (p < 0.001). CONCLUSIONS This retrospective study showed that patients with meningioma with ER-positive expression had a much worse prognosis than those with ER weak-positive or ER-negative status. The results demonstrated that ER is an independent prognostic factor for both PFS and OS of patients with WHO Grade III meningioma. The authors also found that more radical resection of the tumor, as well as postoperative radiotherapy, may prolong patients' survival time.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Hua L, Zhu H, Li J, et al. Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution. J Neurosurg. 2017. PMID: 28820306. doi:10.3171/2017.2.JNS162566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。